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Introduction
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of lymphoproliferative disorders of the skin 1 and are regarded as a subset of extranodal non-Hodgkin's T cell lymphomas of skin-homing memory T cells 2 . Among CTCL patients with peripheral blood involvement, there are greater numbers of T cells expressing the skin-homing cutaneous lymphocyte antigen (CLA) and the chemokine receptor CCR4 than are present in healthy normal donors 3 . Furthermore, the CCR4 ligand CCL17 is highly expressed on the endothelial cells in CTCL skin lesions 3 . These findings, together with the increased expression of E-selectin and ICAM-1 in CTCL lesions 4, 5 , suggest that the appropriate microenvironment exists for the entry of skin-homing T cells into CTCL lesions 3 . These malignant T cells may be found singly or collectively within the epidermis and admixed with an infiltrate of mononuclear cells within the papillary dermis underlying the involved epidermis.
We recently reported that in all cases of advanced CTCL, and many cases of early disease, there is a significant disruption of the diversity of the T cell repertoire in peripheral blood 6 . T cell receptor beta-variable (BV) spectratyping revealed diminished complexity in many BV families 6 , and this correlated with diminished T-cell receptor excision circles (TREC) levels 7 . Both observations are consistent with the idea that some normal T cells are being removed from circulation, and other T cells are proliferating to fill the space that this removal creates in the T cell compartment. The idea that there may be a proliferative stimulus in the peripheral blood of CTCL patients led us to examine peripheral blood plasma for the presence of T cell trophic cytokines. Patients and normal controls were studied, and plasma levels of Interleukin (IL)-2, IL-4, IL-7, IL-12, IL-13, and IL-15 were measured. In preliminary studies, only IL-7 was reproducibly increased
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It has been appreciated for many years that resident cells of skin, including keratinocytes and fibroblasts, can produce a wide variety of cytokines [8] [9] [10] [11] . One such cytokine is IL-7. IL-7 is a single-chain 25-kDa molecule that is important for both T and B cell growth and development [12] [13] [14] [15] [16] [17] [18] . It is unique in its ability to both increase the generation of naive T cells by the thymus [12] [13] [14] [15] [16] and promote the survival of mature T cells [19] [20] [21] [22] in the blood and lymph nodes, thus maintaining homeostasis in the T cell compartment. IL-7 increases the survival of T cells in part by increasing the expression of anti-apoptotic factor Bcl-2 23 . It is interesting that elevated levels of plasma IL-7 have been found in conditions of T cell depletion, including after chemotherapy and HIV infection [24] [25] [26] , and IL-7 levels are inversely correlated with CD4 levels 24, 25 . These studies support the notion that increased production of IL-7 may be a homeostatic mechanism for regulating T-cell proliferation and possibly thymic output 24, 25 . IL-7 is also involved in the growth and survival of Sezary cells 27, 28 . Because CTCL cells may remain restricted to the skin during the course of the disease, locally produced IL-7 may be important for the survival of T cells.
In this study, we investigated plasma IL-7 levels in 93 CTCL patients, and further measured lesional IL-7 mRNA expression levels in skin lesions from 10 CTCL patients; both were compared to normal plasma and skin, respectively. In addition, we cultured explants of normal and CTCL skin on specialized matrices that we have previously shown to support the survival of resident cells in normal skin*. These cultures were assayed for IL-7 protein, and the ability of the conditioned medium to support T cell growth. Our results show that IL-7 is significantly increased in the plasma of CTCL patients, and that CTCL skin contains mRNA for IL-7 and produces protein identical to After informed consent, biopsy samples were taken from skin lesions of 18 CTCL patients (10 men and 8 women; median age, 62 years, range 29-94) under local lidocaine anesthesia. None of the patients had received any ultraviolet treatment, systemic drug therapy, or topical corticosteroids for at least 3 weeks before the investigation. Ten normal human skin samples were obtained as discarded tissue from cutaneous surgeries and were cut into 6-× 6-mm pieces, the same size as the biopsy specimens from CTCL patients. All studies using blood and skin biopsy samples were approved by the Dana-Farber Cancer Institute Institutional Review Board.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
Plasma preparation
Plasma samples were isolated from heparinized venous blood by density gradient centrifugation over Ficoll (Histopaque, Sigma, St. Louis, MO). All plasma samples were stored at -80 o C prior to use.
Quantification of cytokines
Cytokine levels in plasma and skin culture supernatants were measured by quantitative sandwich enzyme-linked immunosorbent assay (ELISA). IL-2, IL-4, IL-7, IL-12, IL-13, and IL-15 ELISAs were purchased from R&D Systems (Minneapolis, MN). Samples were thawed at room temperature and assayed in duplicate. The reproducibility of the ELISA was assessed through the incorporation of a control plasma sample in each assay. β-actin: GTGGGGCGCCCCAGGCACCA and CTCCTTAATGTCACGCACGATTTC.
Quantification of levels of cytokine mRNA
A series of standard dilutions of a plasmid were used to quantify cytokines and enzyme.
Specific signals for all transcripts were readily detected in human normal fibroblasts.
Standard dilutions are amplified with pGEM-T Easy Vector Systems (Promega, Madison, WI) from the PCR amplifiers above. PCR was conducted with 40 cycles, which were within the linear amplification range for PCR reactions. For all of these samples, PCR was conducted twice. The specificity of the PCR products was confirmed by sequence analysis.
Preparation of keratinocyte and fibroblast cell cultures from skin biopsy
Keratinocytes were isolated by incubation of normal control skin specimens in 2.4 U/ml dispase II (Roche, Indianapolis, IL) overnight at 4 o C; subsequent removal of the epidermis sheet with tweezers was followed by incubation for 5 min at 37 o C in PBS containing 0.25% trypsin and 0.1% EDTA. Keratinocytes were grown in Keratinocyte-SFM (Gibco, Carlsbad, CA) supplemented with 75 µg/ml bovine pituitary extract (Gibco), 0.2 ng/ml EGF (Gibco), 0.3 mM CaCl 2 , 100 IU/ml penicillin, and 100 µg/ml streptomycin (PCN/Strep). Fibroblasts were isolated by mincing normal donor dermal skin fragments and incubating the fragments in HBSS with 2.5 mg/ml trypsin and 5 mg/ml collagenase for 1 hour. Fibroblasts were cultured in DMEM/F12 (Gibco)
supplemented with 15% FCS (Sigma, St. Louis, MO), 10 ng/ml EGF, and PCN/Strep*.
Third-passage samples from normal keratinocytes and fibroblasts were used to quantify cytokine mRNA. After cells were harvested for 2 days, they were washed twice with PBS and collected, and mRNA was purified as described above.
Preparation of three-dimensional skin explant cultures
To analyze cytokines produced by skin in a culture condition which mimics lymphocyte-tissue interactions in the skin, we developed a three-dimensional skin explant culture system (details in *). Briefly, 9-× 9-× 1.5-mm Cellfoam matrices (Cytomatrix, Woburn, MA) were autoclaved and incubated in a solution of 100 µg/ml rat tail collagen I (BD Biosciences, Bedford, MA) in PBS for 30 min at 37 o C. A punch biopsy was taken from lesional CTCL skin or from normal discarded skin, subcutaneous fat was removed, and the tissue was minced into explants approximately 2 × 2 × 2 mm.
Three skin explants were placed on the surface of each matrix, and the culture was maintained in Iscove's modified medium (Mediatech, Herndon, VA) with 10%
heat-inactivated FBS (Sigma), PCN/Strep, and 3.5 µl/L β-mercaptoethanol. The culture was maintained for 5 weeks, and one-half of the skin-culture supernatant was collected and replaced three times weekly. The produced T cells were collected once a week for up to 5 weeks. In this system, keratinocytes and dermal fibroblasts grow and spread into
Cellfoam matrices, and skin-residing T cells are observed to spill out of the matrices into the culture wells. Skin lesions themselves are simulated for more than 5 weeks. We also cultured these skin explants with anti-human IL-7 neutralizing antibody or recombinant human IL-7, IL-4 and/ or IL-13; anti-IL-7 antibody (25 ng/ml) or recombinantIL-7, IL-4 and IL-13 (25 ng/ml) was mixed in the culture medium from day 1. Eight CTCL skin samples and eight control samples were collected for this experiment. were injected into the matrices and incubated for 1 hour at 37°C. Finally, 2 ml of Iscove's modified medium was added carefully and the culture was incubated at 37°C for 1 week.
One-half of the medium was removed and replaced every other day, and produced T cells were collected on day 7. Cells were acquired in a FACScan, and CFSE levels were analyzed using CellQuest software (both Becton Dickinson, Mountain View, CA). We also cultured the skin explant with anti-human IL-7 neutralizing antibody (25 ng/ml) from day 1.
Statistical analyses
Linear regression models were fitted to the plasma IL-7 data from all patients. The models included the log 10 of the plasma IL-7 levels as the dependent variable and age, gender, and stage as the independent variables. The Wilcoxon-Mann-Whitney test was used to evaluate differences in mRNA expression levels, IL-7 concentration in the supernatant from skin explants and normal skin cells, and T cell yields between CTCL and normal control skin samples.
For
Results

Plasma cytokine levels
Plasma cytokine levels of 93 patients and 20 controls were measured by ELISA. Levels of IL-2, 4, 12, and 13 were all below the level of detection. In contrast, IL-7and IL-15
were both detectable in plasma of most patients and controls. There was no significant difference in the circulating levels of IL-15 between normal controls and CTCL patients (data not shown). However, IL-7 values from plasma were elevated in patients with CTCL, and these results were further analyzed. The log transform, when applied to the plasma IL-7 data, made the data symmetric. Therefore, a linear regression model was fitted to the log 10 of plasma IL-7 data, with age, gender, and stage as covariates (Figure 1 ).
All stages of CTCL showed significant differences compared with the normal cohort, but no significant differences were seen for age and gender. A multiple comparison procedure was used to determine the differences between the stages; however, no significant differences were seen. Therefore, patients with staging data were combined into a single group and compared to the group of healthy volunteers. The linear regression model was fitted again with the following covariates; age, gender and presence or absence of disease, defined as CTCL vs. normal. The results are shown in Figure 1 . Only the patients' identity as CTCL vs. normal was a significant covariate.
Expression of IL-7 mRNA in skin
We next studied the expression of IL-7 mRNA by quantitative PCR analysis. Figure 2A shows the levels of mRNA expression in normal skin (n=10) and CTCL lesional skin (n=10). The nonparametric two-sided Wilcoxon-Mann-Whitney test was used to compare For personal use only. on September 14, 2017. by guest www.bloodjournal.org From the cytokine levels of CTCL lesions with those of normal skin samples; the two-sided p-values were 0.0001. These data demonstrate that the message for IL-7 is constitutively expressed at a low level in human normal skin, but at a significantly higher level in CTCL skin lesions. We found no statistically significant differences between the expression of IL-7 by keratinocytes and fibroblasts cultured from normal skin (p-value = 0.3823) ( Figure 2B) ; thus, the source of IL-7 in CTCL skin is obscure.
IL-7 concentration in supernatants from CTCL and normal skin explant cultures
Supernatants from three-dimensional skin explant culture systems were collected at week 3 and analyzed for IL-7 production by ELISA. The two-sided Wilcoxon-Mann-Whitney test was used to assess the differences between 8 normal controls and 8 CTCL patients.
The IL-7 concentration in medium conditioned by CTCL explants was significantly higher than in normal controls (p-value = 0.0001) (Figure 3 ). Lesional lymphocytes in CTCL produce T helper (Th) 2 cytokines, and we reasoned that the production of these in situ might increase the levels of IL-7 present. However, levels of IL-7 from normal skin explant cultures, treated with or without Th2 cytokines, were never as high as those observed in CTCL samples. In addition, we found no detectable levels of IL-2 and IL-15 in skin explant cultures from either normal or CTCL skin (data not shown).
Production of T cells by skin matrix explant cultures
We have reported elsewhere that skin explants cultured on matrices gradually release large numbers of skin resident T cells into the medium over a period of weeks*. We harvested and counted the T cells produced by skin matrix cultures from both normal and CTCL patients once each week. The two-sided Wilcoxon-Mann-Whitney test was used to These cultures released T cells at levels close to those seen in CTCL skin explants. We hypothesized that IL-7 produced by the CTCL explant cultures could be responsible for the increased number of T cells observed. Consistent with our hypothesis, the addition of anti-human IL-7 neutralizing antibody to CTCL skin matrix significantly decreased the T cell yield from these cultures (Figure 4 ).
Proliferation of normal T cells induced by CTCL skin cells
The data obtained thus far suggested that CTCL skin is an environment that supports Similar results were obtained in three independent experiments.
Discussion
In this study, we measured the levels of T lymphotropic cytokines in the plasma of normal controls and a large population of CTCL patients. Of six cytokines measured, only IL-7 showed statistically significant and reproducible elevations in patients with CTCL. These elevations were found at all stages, and in fact stage was not a significant covariate. We further demonstrated that increased levels of IL-7 mRNA were present in lesional CTCL skin as compared to normal skin, and that explants of CTCL skin released more IL-7 into the medium than did normal skin explants. In parallel, CTCL explant cultures resulted in the release of many more T cells from skin than normal explants.
Importantly, this yield of T cells from CTCL explants could be reduced significantly if antibodies to IL-7 were added. Finally, we demonstrated that CTCL explant cultures could support the presumably antigen independent proliferation of normal skin homing memory T cells, while normal skin explants could not. This too could be blocked by antibodies to IL-7. Taken together, these data point to production of IL-7 by CTCL skin as an important feature of this disease. IL-7 is thought to be produced predominately by epithelial and stromal cells in the thymus, lymph nodes, and bone marrow [30] [31] [32] , and is a critical factor in both B-and T-cell development 12-18,33,34 . Furthermore, it enhances both thymic and extra-thymic lymphopoesis in the context of diseases that result in lymphopenia. IL-7 treatment can induce the expansion of naive T cells without antigenic stimulation 35, 36 or differentiation into memory T cell 37,38 .
We reported previously that the diversity of the T-cell repertoire in CTCL is significantly contracted 6 , despite the presence of a relatively normal absolute T cell counts 39, 40 . We have postulated that this contraction of the T-cell repertoire contributes to the immune suppression and significant infection-related mortality that characterizes advanced disease. We also reported that the levels of TRECs in patients with CTCL were decreased, even in early stage disease 7 . could be reproducibly measured in the plasma of patients and controls. While IL-15 levels did not differ between patients and controls, plasma IL-7 levels were significantly higher in CTCL patients than in normal controls. This increase appeared to be independent of stage, though there was a trend towards higher levels in patients with stage II and III disease. We next investigated whether CTCL skin could be the source of the increased circulating levels of IL-7 in these patients. Using a sensitive and specific quantitative PCR assay, we found higher levels of IL-7 mRNA in CTCL skin than in normal skin.
Because cytokine mRNA expression and protein production do not always correlate, we felt it was necessary to measure cytokine protein production in CTCL skin.
Direct quantitative IL-7 protein measurements from skin were impractical, so we employed a three-dimensional matrix skin explant culture system to simulate intact normal and CTCL skin*. Periodically, the medium conditioned by these explants was sampled and tested for cytokines including IL-7. Our results indicated that IL-7 was produced at much higher levels in CTCL explant cultures as compared to normal skin CTCL is thought to be a Th2 disease, and clonal CTCL cells produce Th2 cytokines [41] [42] [43] [44] . To assess whether Th2 cytokines produced by clonal CTCL cells can stimulate IL-7 production by resident skin cells, we incubated normal skin explant cultures with the Th2 cytokines IL-4 and/or IL-13. We found no production of IL-7 at levels comparable to those observed in CTCL explant cultures (Figure 3 ), suggesting that these T cell cytokines do not stimulate skin cells in the explant cultures to produce IL-7.
When fibroblasts and keratinocytes from CTCL lesions were grown in two-dimensional culture in the absence of lymphocytes, these cultures produced only low levels IL-7 (data not shown). Subsequent addition of autologous CD3 + T cells to these two-dimensional CTCL skin cell cultures did not restore IL-7 production (data not shown). These results suggest that close cell-to-cell interactions between lymphocytes and skin-construct fibroblasts and keratinocytes in a three-dimensional arrangement might be required for efficient production of IL-7. We have reported previously that explants of skin placed on the Cellfoam three-dimensional matrices produce significant numbers of T cells that However, treatment of normal skin explants with IL-7 increased T cell production to levels observed in CTCL skin. Lastly, addition of anti-human IL-7 neutralizing antibody to CTCL explants dramatically decreased the number of cells produced (Figure 4) .
Interestingly, when we cultured psoriasis skin on the same matrix, IL-7 levels in the supernatant were as low as those from normal skin explants, and the number of T cells produced from psoriasis skin explants was similar to that from normal skin explants (data not shown).
These data demonstrate that skin-derived IL-7 can promote the proliferation of lymphocytes in CTCL skin lesions. To confirm that CTCL-skin derived IL-7 can induce the proliferation of skin-homing T cells, we added CLA + T cells from peripheral blood to matrices colonized with skin cells from either normal or CTCL skin. Skin homing T cells present in normal skin also express high levels of CLA 3, 45 . Our data clearly demonstrated that IL-7 produced in CTCL skin can support the proliferation of CLA + T cells derived from peripheral blood, a process that can be inhibited by antibody to IL-7 ( Figure 5 ). We performed the same experiment with psoriasis skin, however we did not detect any proliferation for the CLA + T cells cultured on the psoriasis skin explants. Thus, the contribution of IL-7 to lymphocytes proliferation appears to be unique to CTCL skin. In conclusion, in CTCL skin lesions where T cells may remain restricted to the skin throughout the course of the disease, local production of IL-7 can strongly influence their survival and proliferation. Figure 1 . Levels of IL-7 in plasma from patients with CTCL. Plasma samples were collected from 93 CTCL patients and 20 normal controls. IL-7 levels were measured by ELISA. IL-7 levels were significantly higher in plasma samples from patients with CTCL. p< 0.001, ** p< 0.01 Figure 2 . Expression of IL-7 mRNA in normal and CTCL skin (A), and in normal keratinocytes and fibroblasts (B) was analyzed by quantitative PCR. The data are shown as a relative quantification of IL-7mRNA expression levels divided by levels of β-actin mRNA. Expression of IL-7 mRNA was significantly higher in CTCL skin lesions than in samples of normal skin (A). * p< 0.001 Figure 3 . IL-7 concentration in supernatants from skin explant cultures. Normal and CTCL skin explants were cultured under various conditions. The concentration of IL-7 in the supernatant was analyzed by ELISA. IL-7 levels were significantly higher in CTCL samples than in normal controls. Treatment with the Th2 cytokines IL-4 and/or IL-13 did not significantly increase IL-7 production. CTCL and normal skin explants were cultured under various conditions and T cell production was assayed. The number of T cells produced from CTCL skin explants was significantly higher than from normal skin explants. Normal skin explants treated with Th2 cytokines IL-4 and/or IL-13 did not produce more T cells. Normal skin explants treated with recombinant human IL-7 produced more T cells than untreated cultures. The addition of anti-human IL-7 neutralizing antibody to CTCL skin explants decreased the numbers of T cells produced. 
Figure Legends
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